Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients
Abstract
Background: Direct acting antivirals (DAAs) have demonstrated remarkable efficacy, in achieving hepatitis C viral (HCV) elimination rates higher than 90%. One particular concern associated with treatment failure is the emergence of resistance associated substitutions (RASs) in the genome. The occurrence of RASs highlights the adaptability and resilience of the HCV. This highlights the importance of RASs mutation, enabling the development of new therapeutic strategies to combat these resistant strains. This study aims to determine the presence of early HCV mutations in chronic hepatitis C in Indonesia and the association between this mutation to the efficacy of sofosbuvir-daclatasvir. Methods: We conducted a prospective longitudinal study in naïve hepatitis C patient population. The virus was examined for RAS by RNA sequencing before starting treatment. RAS mutations were determined through the cut-off value of RAS mutations that contributed in the successful therapy. All patients were followed up until 12 weeks after completion of treatment to determine the sustained virological response 12 (SVR12). Results: Out of the 58 patients, 9 patients (15.51%) did not achieve SVR. Only 14 patients was further analyzed to provide the association between the mutation and SVR-12 failure after sofosbuvir-daclatasvir therapy. Specifically, 2 patients with L31 mutation and one patient with L31/Y93 mutation achieved SVR. Only one patient with failure to achieve SVR and the mutation was found in Y93H region. Conclusion: The mutation of Y93H may contribute to treatment failure while L31A may increase the susceptibility to DAAs treatment.
Keywords
References
Hasan I, Sulaiman A, Lesmasna C, et al. Konsensus Nasional Penatalaksanaan Hepatitis C di Indonesia 2017. Jakarta: Perhimpunan Penelitis Hati Indonesia (PPHI); 2017.
Global hepatitis report, 2017 [Internet]. [cited 2024 Apr 19]. Available from: https://www.who.int/publications-detail-redirect/9789241565455
Bagaglio S, Uberti-Foppa C, Morsica G. Resistance mechanisms in Hepatitis C virus: implications for direct-acting antiviral use. Drugs. 2017;77(10):1043–55.
Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69(5):1178–87.
Li DK, Chung RT. Overview of direct-acting antiviral drugs and drug resistance of Hepatitis C virus. Methods Mol Biol Clifton NJ. 2019;1911:3–32.
Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461–511.
AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(10):1477–92.
Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res. 2015;6(3):301–10.
Howe AYM, Rodrigo C, Cunningham EB, et al. Characteristics of Hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep Innov Hepatol. 2022;4(5):100462.
Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504.
Global health sector strategy on viral hepatitis 2016-2021. Geneva, Switzerland: World Health Organization; 2016.
Rencana Aksi Nasional Pengendalian Hepatitis 2020-2024. Jakarta, Indonesia: Kementerian Kesehatan Republik Indonesia; 2020.
Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J Hepatol. 2017;66(5):910–8.
Sharafi H, Maleki S, Alavian SM. Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. Virus Res. 2019;259:54–61.
Carrasco I, Arias A, Benítez-Gutiérrez L, et al. Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients. J Med Virol. 2018;90(3):532–6.
Tsuji K, Kurosaki M, Itakura J, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018;53(10):1142–50.
Mawatari S, Oda K, Tabu K, et al. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. PloS One. 2018;13(6):e0198642.
Gozlan Y, Ben-Ari Z, Moscona R, et al. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients. Antivir Ther. 2017;22(5):431–41.
Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501-512.e1.
Kozuka R, Hai H, Motoyama H, et al. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. J Viral Hepat. 2018;25(5):535–42.
Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70–86.
Brandão R, Marcelino R, Gonçalves F, et al. Characterization of NS5A and NS5B resistance-associated substitutions from genotype 1 Hepatitis C virus infected patients in a Portuguese cohort. Viruses. 2018;10(5):223.
Lusida MI, Nagano-Fujii M, Nidom CA, et al. Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of Hepatitis C virus subtypes 1b, 1c, and 2a. J Clin Microbiol. 2001;39(11):3858–64.
Morishita N, Sakamori R, Yamada T, et al. Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection. PLOS ONE. 2020;15(6):e0234811.
Ruiz I, Fourati S, Ahmed-Belkacem A, et al. Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders. Eur J Gastroenterol Hepatol. 2021;33(1S):e191.
Krishnan P, Tripathi R, Schnell G, et al. Resistance Analysis of baseline and treatment-emergent variants in Hepatitis C virus genotype 1 in the AVIATOR study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir. Antimicrob Agents Chemother. 2015;59(9):5445–54.
Ueno T, Osawa M, Imai Y, Ishikawa H, Garimella T. Exposure‐response (efficacy) analysis of daclatasvir and asunaprevir in Japanese patients with Hepatitis C virus infection. J Clin Pharmacol. 2018;58(11):1479–88.
Dietz J, Susser S, Vermehren J, et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology. 2018;154(4):976-988.e4.
von Massow G, Garcia-Cehic D, Gregori J, et al. Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype. Infect Drug Resist. 2019;12:947–55.
Refbacks
- There are currently no refbacks.